Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EXACT Therapeutics AS ( (DE:56F) ) has provided an update.
EXACT Therapeutics AS has been granted a U.S. patent for its ultrasound-mediated drug delivery technology, which includes the proprietary agent PS101 and Acoustic Cluster Therapy (ACT®). This patent strengthens EXACT’s position in the U.S., the largest pharmaceutical market, and supports their ongoing Phase 2 trial for pancreatic cancer treatment, marking a significant milestone in their development efforts.
More about EXACT Therapeutics AS
EXACT Therapeutics AS is a clinical-stage precision medicine company specializing in targeted drug delivery in oncology using ultrasound and microbubbles. Their proprietary Acoustic Cluster Therapy (ACT®) can be applied to a variety of therapeutic agents in oncology and other indications such as brain diseases. The company is publicly traded on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 31,429
Current Market Cap: NOK178.4M
For a thorough assessment of 56F stock, go to TipRanks’ Stock Analysis page.